Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

Market: Pharmaceuticals and Healthcare

Global, 319 pages report, published by GlobalData

Report ThumbnailFebruary-2018
Age-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026

Summary

There are two clinical forms of age-related macular degeneration (AMD): dry and wet. Currently there are therapies available only for wet AMD. Drugs in late stages of development target the wet AMD segment and the late stage or atrophic form of dry AMD, called geographic atrophy (GA). The global markets are currently overwhelmingly dominated by anti-VEGFs for wAMD, including Lucentis, Eylea, and Avastin,

Read More
  • 1.2 List of Figures
  • Figure 1: Global Sales Forecast by Country for AMD in 2016 and 2026 15
  • Figure 2: Company Portfolio Gap Analysis in AMD During the Forecast Period 17
  • Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of AMD During the Forecast Period 20
  • Figure 4: Anatomy of the Eye and Macula: Healthy, dAMD, and wAMD 30
  • Figure 5: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages ≥50 Years, 2016 44
  • Fi
Read More
  • 1.1 List of Tables
  • Table 1: AMD: Key Metrics in the 7MM 11
  • Table 2: Biological Pathways Associated with AMD Risk Genes 37
  • Table 3: The Four-Stage AREDS Classification of AMD 38
  • Table 4: Symptoms of AMD 40
  • Table 5: Severity Scale to Assess Five-Year Risk of Progression to Advanced AMD 41
  • Table 6: Risk Factors and Comorbid Conditions Associated with AMD 43
  • Table 7: Classification of AMD 45
  • Table 8: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages ≥50 Years, N, Selected Years 2016-2026 55
  • Table
Read More
  • 1 Table of Contents
  • 1 Table of Contents 2
  • 1.1 List of Tables 8
  • 1.2 List of Figures 10
  • 2 Age-Related Macular Degeneration: Executive Summary 11
  • 2.1 Significant Growth Expected in the AMD Market from 2016 to 2026 12
  • 2.2 R&D and Corporate Strategies Within the AMD Market 15
  • 2.3 Current Therapies for AMD Leave Abundant Unmet Needs 17
  • 2.4 Opportunities Will Remain for New Entrants 18
  • 2.5 Late-Stage Pipeline Drugs Entering the AMD Market Will Be a Key Driver of Growth 19
  • 2.6 What Do Physicians Think?
Read More

Please select a license type

Share

Related Products

GlobalDataAge-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026Product ThumbnailAge-Related Macular Degeneration: Global Drug Forecast and Market Analysis to 2026, Industry ReportProduct #: 1177805
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2018 Global Market Analyst. All Rights Reserved